Duvelisib

Drug Profile

Duvelisib

Alternative Names: ABBV-954; INK-1197; IPI-145

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intellikine
  • Developer AbbVie; Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Verastem
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Isoquinolines; Nonsteroidal anti-inflammatories; Purines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Phase I Haematological malignancies; Lymphoma
  • Preclinical Solid tumours
  • Discontinued Allergic asthma; Rheumatoid arthritis

Most Recent Events

  • 08 Aug 2017 Updated efficacy data from the phase II DYNAMO trial in Non-Hodgkin's lymphoma released by Verastem
  • 28 Jul 2017 Infinity Pharmaceuticals withdraws the FRESCO trial prior to enrolment in Follicular lymphoma (Combination therapy, Second-line therapy or greater) in USA, Spain and Hungary as the sponsor is focusing on studies which can enable registration of duvelisib (PO) (NCT02605694)
  • 07 Jun 2017 Efficacy and adverse events data from a phase II trial in Non-Hodgkin's lymphoma released by Verastem
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top